Open an account

argenx SE

ARGX · NYSE

$873.71−$2.06 (−0.23%)TodayMarket closed ·
Prev close $875.76

About ARGX

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Employees
1,599
Headquarters
Amsterdam, Noord-Holland
Listed
Jul 10, 2014
Sector
Health Care
Industry
Biotechnology
Website
argenx.com

ARGX key statistics

Market cap
49.26B
Price-earnings ratio
44.75
Dividend yield
—
Average volume
511.85K
Volume
298.93K
Open price
$875.25
High today
$887.07
Low today
$865.72
52 Week high
$1,072.75
52 Week low
$661.85

argenx SE (ARGX) at a glance

As of Oct 23, 2026, argenx SE (ARGX) shares are priced at $873.71, giving the company a market cap of 49.26B and a price-to-earnings ratio of 44.75.

Today the stock has traded between $865.72 and $887.07. The current price is 0.9% above the day's low and 1.5% below its high.

Volume so far is 298.93K shares, below the average of 511.85K shares a day.

Over the past year argenx SE has ranged from $661.85 to $1,072.75, and now sits 52% of the way up that range.

argenx SE met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported $7.80 per share against an estimate of $8.20.

The average analyst price target is $1,157.48, 32.5% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

90%of 21 analyst ratings say Buy
  • Buy90.5%
  • Hold9.5%
  • Sell0.0%
Price target · 19 analystsAvg $1,157.48
Low
$834.27
Now
$873.71
High
$1,425.71

ARGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 16.0% on average.

  1. Q4 FY24: reported $0.93 per share against an estimate of $1.50
  2. Q1 FY25: reported $2.58 per share against an estimate of $2.41
  3. Q2 FY25: reported $3.74 per share against an estimate of $3.04
  4. Q3 FY25: reported $5.18 per share against an estimate of $4.37
  5. Q4 FY25: reported $8.02 per share against an estimate of $6.25
  6. Q1 FY26: reported $5.52 per share against an estimate of $5.42
  7. Q2 FY26: reported $7.33 per share against an estimate of $6.29
  8. Q3 FY26: reported $7.80 per share against an estimate of $8.20

ARGX news

  • Press releaseBusiness Wire

    ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

  • Press releasePRNewswire

    argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)

  • Avi Kapoor

    Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

  • Vandana Singh

    Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis

  • Avi Kapoor

    Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

  • Avi Kapoor

    These Analysts Boost Their Forecasts On Argenx

  • Avi Kapoor

    Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

  • Vandana Singh

    Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal

Similar companies

Companies in the same industry as argenx SE

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.